Search - tctmd.com

Displaying 41 - 60 of 145

Sort: Relevancy | Date

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

April 03, 2022

Better Angina Relief With Complete PCI in STEMI and MVD

News Conference News ACC 2022

Better Angina Relief With Complete PCI in STEMI and MVD

April 02, 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

April 02, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

FFR Doesn’t Beat Angio for Complete Revasc in STEMI: FLOWER-MI

News Conference News ACC 2021

FFR Doesn’t Beat Angio for Complete Revasc in STEMI: FLOWER-MI

May 25, 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

May 21, 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

News Conference News ACC 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

May 16, 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

May 16, 2021

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

News Conference News ACC 2021

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

May 15, 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

Survival Benefit Shown for Radial Artery Grafting in CABG

News Conference News ACC 2020

Survival Benefit Shown for Radial Artery Grafting in CABG

March 30, 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

News Conference News ACC 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

March 29, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.